The dark side of Toll-like receptor signaling: TLR9 activation limits the efficacy cancer radiotherapy

Radiation therapy is potentially immunogenic yet it rarely generates long-term antitumor effects. We have recently demonstrated that Toll-like receptor 9 (TLR9) jump-starts the signal transduction and activator of transcription 3 (STAT3)-dependent vascularization and regrowth of tumors that recur up...

Descripción completa

Detalles Bibliográficos
Autores principales: Kortylewski, Marcin, Pal, Sumanta K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2014
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4203530/
https://www.ncbi.nlm.nih.gov/pubmed/25340001
http://dx.doi.org/10.4161/onci.27894
_version_ 1782340406468411392
author Kortylewski, Marcin
Pal, Sumanta K
author_facet Kortylewski, Marcin
Pal, Sumanta K
author_sort Kortylewski, Marcin
collection PubMed
description Radiation therapy is potentially immunogenic yet it rarely generates long-term antitumor effects. We have recently demonstrated that Toll-like receptor 9 (TLR9) jump-starts the signal transduction and activator of transcription 3 (STAT3)-dependent vascularization and regrowth of tumors that recur upon irradiation. We propose that the targeted inhibition of the TLR9/STAT3 signaling axis in myeloid cells can support the efficacy of local radiotherapy and prevent cancer recurrence.
format Online
Article
Text
id pubmed-4203530
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-42035302015-02-14 The dark side of Toll-like receptor signaling: TLR9 activation limits the efficacy cancer radiotherapy Kortylewski, Marcin Pal, Sumanta K Oncoimmunology Author's View Radiation therapy is potentially immunogenic yet it rarely generates long-term antitumor effects. We have recently demonstrated that Toll-like receptor 9 (TLR9) jump-starts the signal transduction and activator of transcription 3 (STAT3)-dependent vascularization and regrowth of tumors that recur upon irradiation. We propose that the targeted inhibition of the TLR9/STAT3 signaling axis in myeloid cells can support the efficacy of local radiotherapy and prevent cancer recurrence. Landes Bioscience 2014-02-14 /pmc/articles/PMC4203530/ /pubmed/25340001 http://dx.doi.org/10.4161/onci.27894 Text en Copyright © 2014 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Author's View
Kortylewski, Marcin
Pal, Sumanta K
The dark side of Toll-like receptor signaling: TLR9 activation limits the efficacy cancer radiotherapy
title The dark side of Toll-like receptor signaling: TLR9 activation limits the efficacy cancer radiotherapy
title_full The dark side of Toll-like receptor signaling: TLR9 activation limits the efficacy cancer radiotherapy
title_fullStr The dark side of Toll-like receptor signaling: TLR9 activation limits the efficacy cancer radiotherapy
title_full_unstemmed The dark side of Toll-like receptor signaling: TLR9 activation limits the efficacy cancer radiotherapy
title_short The dark side of Toll-like receptor signaling: TLR9 activation limits the efficacy cancer radiotherapy
title_sort dark side of toll-like receptor signaling: tlr9 activation limits the efficacy cancer radiotherapy
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4203530/
https://www.ncbi.nlm.nih.gov/pubmed/25340001
http://dx.doi.org/10.4161/onci.27894
work_keys_str_mv AT kortylewskimarcin thedarksideoftolllikereceptorsignalingtlr9activationlimitstheefficacycancerradiotherapy
AT palsumantak thedarksideoftolllikereceptorsignalingtlr9activationlimitstheefficacycancerradiotherapy
AT kortylewskimarcin darksideoftolllikereceptorsignalingtlr9activationlimitstheefficacycancerradiotherapy
AT palsumantak darksideoftolllikereceptorsignalingtlr9activationlimitstheefficacycancerradiotherapy

Ejemplares similares